ESC Premium Access

Hyperuricemia impaired nitric oxide bioavailablity and deteriorated pulmonary arterial hypertension via a uric acid transporter, URATv1 in xanthine oxidoreductase (XOR)-independent manner

Topic: Hypertension, Pulmonary Hypertension

Congress Presentation

About the speaker

Doctor Takanori Watanabe

Kyushu University Hospital, Fukuoka (Japan)
0 follower

6 more presentations in this session

A novel three-dimensional visualization system revealed an essential adaptive angiogenic response during the early phase of pulmonary hypertension

Speaker: Doctor T. Fujiwara (Tokyo, JP)

Thumbnail

Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction

Speaker: Professor V. Schini-Kerth (Strasbourg, FR)

Thumbnail

Pulmonary hypertension: reduction of vascular and cardiac remodeling by a new inhibitor of p38-alpha MAPK

Speaker: Miss G. Silva (Rio de Janeiro, BR)

Thumbnail

Selective inhibition of Histone deacetylases reverses vascular remodelling and improves right ventricle function in pulmonary hypertension

Speaker: Doctor K. Kurakula (Amsterdam, NL)

Thumbnail

Beta3-adrenergic stimulation restores endothelial mitochondrial dynamics and prevents pulmonary arterial hypertension

Speaker: Doctor E. Oliver (Madrid, ES)

Thumbnail

Access the full session

Pulmonary Hypertension: Targets for Therapies

Speakers: Doctor T. Watanabe, Doctor T. Fujiwara, Professor V. Schini-Kerth, Miss G. Silva, Doctor K. Kurakula...
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations